A Real World Study of Ensartinib in Advanced ALK-positive NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC — Stella

Home/Carcinoma, Non-Small-Cell Lung/

View on ClinicalTrials.gov

Recruiting

Back to Carcinoma, Non-Small-Cell Lung trials

Trial locations(1 site)

China

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing Municipality

Key details

Sponsor

Peking Union Medical College Hospital

Collaborators

Betta Pharmaceuticals Co., Ltd.

Enrollment target

~490 participants

Started

May 2022

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated August 2022

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.